# How Special Molecules Boost Cancer-Fighting CAR-T Cells > This patent describes special molecules made of a CAR-T cell activator attached to a fat-like part, designed to make cancer-fighting CAR-T cells grow and work better inside a patient. - **Patent:** US 20240082373 - **Original title:** Compositions for chimeric antigen receptor t cell therapy and uses thereof - **Owner:** Massachusetts Institute of Technology - **Status:** Active - **Times cited:** 2 - **Field:** biotech, pharmaceutical, gene_editing, immunology, oncology ## What it does The patent describes a method (Claim 77) to make chimeric antigen receptor-T (CAR-T) cells more active and numerous in a patient. It does this by giving the patient an "amphiphilic ligand conjugate." This conjugate has two main parts: a "chimeric antigen receptor (CAR) ligand" and a "lipid" (Claim 77). The CAR ligand is like a key that specifically binds to the CAR "lock" on the CAR-T cells, telling them to multiply. The lipid part (Claim 78) helps the conjugate insert into cell membranes, like those of antigen-presenting cells in lymph nodes (Claim 92), and can also bind to albumin in the body. This delivery system helps the CAR-T cells get the signal they need to fight cancer more effectively (Claim 97). For example, a patient with cancer could be given these conjugates, potentially along with their CAR-T cells (Claim 96), to enhance the CAR-T cells' ability to attack tumor cells (Claim 101). ## What it does NOT cover - Does not cover methods of activating CAR-T cells outside a living subject (e.g., in a lab dish), as Claim 77 specifies "in a subject." - Does not cover CAR-T cell activation using a ligand that is not operably linked to a lipid to form an amphiphilic conjugate (Claim 77). - Does not cover CAR-T cell activation where the lipid part does not insert into a cell membrane or bind albumin under physiological conditions (Claim 78). - Does not cover methods where the CAR ligand is not designed to bind to the CAR of the CAR-T cells (Claim 77). - Does not cover CAR-T cell therapies that do not involve administering an amphiphilic ligand conjugate to the subject. ## The clever bit The novelty lies in creating an "amphiphilic ligand conjugate" (Claim 77) that combines a CAR-T activating signal with a lipid. This lipid allows the conjugate to naturally insert into cell membranes and traffic to lymph nodes (Claim 91, 92), effectively delivering the activation signal to CAR-T cells where they are most needed. ## Real-world examples 1. CAR-T cell therapies for blood cancers (e.g., Kymriah, Yescarta) 2. Immunotherapy approaches for solid tumors 3. Drug delivery systems utilizing lipid conjugates 4. Lymph node targeting drug delivery ## Why it matters CAR-T cell therapy is a powerful new way to fight certain cancers, but sometimes the CAR-T cells don't multiply enough or stay active long enough in the patient. This patent offers a way to boost their numbers and activity directly within the body (Claim 77). By making CAR-T cells more effective, this technology could improve treatment outcomes for patients with cancer (Claim 97) and potentially expand the types of cancers that can be treated. ## Frequently asked questions ### What does How Special Molecules Boost Cancer-Fighting CAR-T Cells cover? This patent describes special molecules made of a CAR-T cell activator attached to a fat-like part, designed to make cancer-fighting CAR-T cells grow and work better inside a patient. ### Who owns patent US 20240082373? This patent is owned by Massachusetts Institute of Technology. ### When does this patent expire? This patent is expected to expire on June 21, 2043, when the invention enters the public domain. ### What is patent US 20240082373 cited by? This patent has been cited by 2 later patents that build on its ideas. ### What problem does this patent solve? CAR-T cell therapy is a powerful new way to fight certain cancers, but sometimes the CAR-T cells don't multiply enough or stay active long enough in the patient. This patent offers a way to boost their numbers and activity directly within the body (Claim 77). By making CAR-T cells more effective, this technology could improve treatment outcomes for patients with cancer (Claim 97) and potentially expand the types of cancers that can be treated. ### What does this patent NOT cover? Does not cover methods of activating CAR-T cells outside a living subject (e.g., in a lab dish), as Claim 77 specifies "in a subject." **Full plain-English explainer:** https://patentbrief.org/patent/us/20240082373/compositions-for-chimeric-antigen-receptor-t-cell-therapy-and-uses-thereof **Original patent:** https://patents.google.com/patent/US20240082373 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._